FGF23 and metabolic syndrome: Considering the fact that increased body mass, dyslipidemia, and increased leptin levels are factors involved in the pathogenesis of endometrial cancer, one should expect that patients with endometrial cancer should also present with higher levels of FGF23 [10,11,12].